These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 14759080)

  • 21. CB(1) receptor antagonism: biological basis for metabolic effects.
    Di Marzo V
    Drug Discov Today; 2008 Dec; 13(23-24):1026-41. PubMed ID: 18824122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats.
    Janiak P; Poirier B; Bidouard JP; Cadrouvele C; Pierre F; Gouraud L; Barbosa I; Dedio J; Maffrand JP; Le Fur G; O'Connor S; Herbert JM
    Kidney Int; 2007 Dec; 72(11):1345-57. PubMed ID: 17882151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cannabinoid-1 receptor inhibition prevents the reduction of 24-hour energy expenditure with weight loss.
    Strack AM; Nicolich S; Faidley T; Achanfuo-Yeboah J; Cunningham PK; Hora D; Thompson D; Hickey G; Johnson-Levonas AO; Fong TM; Heymsfield SB
    Metabolism; 2012 Apr; 61(4):546-53. PubMed ID: 22001334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The endocannabinoid system: a new target for the regulation of energy balance and metabolism.
    Després JP
    Crit Pathw Cardiol; 2007 Jun; 6(2):46-50. PubMed ID: 17667864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.
    Ward SJ; Raffa RB
    Obesity (Silver Spring); 2011 Jul; 19(7):1325-34. PubMed ID: 21475141
    [No Abstract]   [Full Text] [Related]  

  • 26. Additive actions of the cannabinoid and neuropeptide Y systems on adiposity and lipid oxidation.
    Zhang L; Lee NJ; Nguyen AD; Enriquez RF; Riepler SJ; Stehrer B; Yulyaningsih E; Lin S; Shi YC; Baldock PA; Herzog H; Sainsbury A
    Diabetes Obes Metab; 2010 Jul; 12(7):591-603. PubMed ID: 20590734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel effects of the cannabinoid inverse agonist AM 251 on parameters related to metabolic syndrome in obese Zucker rats.
    Merroun I; Sánchez-González C; Martínez R; López-Chaves C; Porres JM; Aranda P; Llopis J; Galisteo M; Zarzuelo A; Errami M; López-Jurado M
    Metabolism; 2013 Nov; 62(11):1641-50. PubMed ID: 23932644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?
    Di Marzo V
    Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):610-2. PubMed ID: 18695695
    [No Abstract]   [Full Text] [Related]  

  • 29. Endocannabinoid system and cardiometabolic risk.
    Saavedra LE
    Clin Pharmacol Ther; 2007 Nov; 82(5):591-4. PubMed ID: 17898706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rimonabant and progression of atherosclerosis in obese persons.
    Dora JM; Scheffel RS
    JAMA; 2008 Jul; 300(3):280; author reply 280-1. PubMed ID: 18632538
    [No Abstract]   [Full Text] [Related]  

  • 31. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors.
    Gelfand EV; Cannon CP
    J Am Coll Cardiol; 2006 May; 47(10):1919-26. PubMed ID: 16697306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long term cannabinoid receptor (CB1) blockade in obesity: implications for the development of colorectal cancer.
    Wright KL; Robertson DA; Moyer MP; Ward SG
    Int J Cancer; 2008 Apr; 122(8):1920-1. PubMed ID: 18076045
    [No Abstract]   [Full Text] [Related]  

  • 33. Endocannabinoid inhibition: a new cardioprotective strategy against doxorubicin cardiotoxicity.
    Fajardo G; Bernstein D
    J Am Coll Cardiol; 2007 Aug; 50(6):537-9. PubMed ID: 17678737
    [No Abstract]   [Full Text] [Related]  

  • 34. Responses to the cannabinoid receptor-1 antagonist, AM251, are more robust with age and with high-fat feeding.
    Judge MK; Zhang Y; Scarpace PJ
    J Endocrinol; 2009 Nov; 203(2):281-90. PubMed ID: 19679649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
    Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR
    Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The endocannabinoid system].
    Sudano I; Périat D; Noll G
    Praxis (Bern 1994); 2008 Apr; 97(7):375-80. PubMed ID: 18548817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. End of the line for cannabinoid receptor 1 as an anti-obesity target?
    Jones D
    Nat Rev Drug Discov; 2008 Dec; 7(12):961-2. PubMed ID: 19043439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The unfolding cannabinoid story on energy homeostasis: central or peripheral site of action?
    Horvath TL
    Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S30-2. PubMed ID: 16570102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Acomplia, an essential medication or a "comfort" product?].
    Nau JY
    Rev Med Suisse; 2006 Nov; 2(85):2516. PubMed ID: 17120725
    [No Abstract]   [Full Text] [Related]  

  • 40. Reply to the letter to the editor "Long-term cannabinoid receptor (CB1) blockade in obesity: implications for the development of colorectal cancer".
    Santoro A; Gazzerro P; Malfitano AM; Pisanti S; Laezza C; Bifulco M
    Int J Cancer; 2008 Jul; 123(1):243-4. PubMed ID: 18395892
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.